MLICM
KYMR icon

Metropolitan Life Insurance Company (MetLife)’s Kymera Therapeutics KYMR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,198
Closed -$88.4K – 1149
2024
Q1 		$88.4K Hold
2,198
– – ﹤0.01% 1118
2023
Q4 		$56K Sell
2,198
-288
-12% -$5.15K ﹤0.01% 1388
2023
Q3 		$34.6K Buy
2,486
+352
+16% +$7.08K ﹤0.01% 1601
2023
Q2 		$49.1K Hold
2,134
– – ﹤0.01% 1426
2023
Q1 		$63.2K Sell
2,134
-246
-10% -$7.93K ﹤0.01% 1257
2022
Q4 		$59.4K Buy
2,380
+95
+4% +$2.53K ﹤0.01% 1358
2022
Q3 		$49.7K Hold
2,285
– – ﹤0.01% 1461
2022
Q2 		$45K Hold
2,285
– – ﹤0.01% 1573
2022
Q1 		$96.7K Sell
2,285
-6,981
-75% -$295K ﹤0.01% 1215
2021
Q4 		$588K Hold
9,266
– – 0.01% 1316
2021
Q3 		$544K Buy
9,266
+704
+8% +$40.8K 0.01% 1404
2021
Q2 		$415K Buy
8,562
+5,383
+169% +$234K 0.01% 1634
2021
Q1 		$124K Hold
3,179
– – ﹤0.01% 2330
2020
Q4 		$197K Buy
+3,179
New +$155K ﹤0.01% 1945

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KYMR Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 2,198 shares — an estimated $88.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KYMR in Q4 2020 and held it in 14 quarters. The position peaked at $588K in Q4 2021. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,198 Kymera Therapeutics shares in Q2 2024, an estimated $88.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Kymera Therapeutics in Q4 2020 and held it in 14 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Kymera Therapeutics position peaked at $588K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.